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Tracking down protein–protein interactions via a
FRET-system using site-speciﬁc thiol-labeling†
B. Söveges,a T. Imre,b Á. L. Póti,c P. Sok,c Zs. Kele,a A. Alexa,c P. Kele a and
K. Németh *a
Förster resonance energy transfer is among the most popular tools to follow protein–protein interactions.
Although limited to certain cases, site-speciﬁc ﬂuorescent labeling of proteins via natural functions by
means of chemical manipulations can redeem laborious protein engineering techniques. Herein we
report on the synthesis of a heterobifunctional tag and its use in site-speciﬁc protein labeling studies
aiming at exploring protein–protein interactions. The oxadiazole-methylsulfonyl functionality serves as a
thiol speciﬁc warhead that enables easy and selective installation of ﬂuorescent labels through a bioortho-
gonal motif. Mitogen activated protein kinase (MAPK14) and its substrate mitogen activated protein kinase
activated kinase (MAPKAP2) or its docking motif, a 22 amino acid-long peptide fragment, were labeled
with a donor and an acceptor, respectively. Evolution of strong FRET signals upon protein–protein inter-
actions supported the speciﬁc communication between the partners. Using an eﬃcient FRET pair allowed
the estimation of dissociation constants for protein–protein and peptide–protein interactions (145 nM
and 240 nM, respectively).
Introduction
The human genome consists of nearly 30 000 genes, coding
over half a million proteins. According to current estimations
ca. 80% of proteins operate in complexes.1 Understanding the
interactions in such protein complexes is important in the
exploration of biochemical processes e.g. antibody–antigen
interactions, signal transduction and regulation or hormone-
receptor binding.2 Nowadays many robust methods are avail-
able for the detection of protein–protein interactions (PPI)
(e.g., aﬃnity blotting, immunoprecipitation, quantitative pro-
teomics, chemical crosslinking).3,4 To investigate protein com-
munication in live cells, however, fluorescence methods e.g.
bimolecular fluorescence complementation (BiFC)5,6 or Förster
resonance energy transfer (FRET) are the methods of choice.
Due to the time requirement for the reporter protein to
mature BiFC cannot provide real-time information on PPIs,
not to mention that the reconstituted fluorescent protein (FP)
remains stable; thus the interaction is irreversible making
BiFC less suitable to determine the dynamic features or spatio-
temporal changes.7
The phenomenon of FRET is a highly distance-dependent
process where an excited-state donor molecule transfers its
energy to the acceptor molecule via non-radiative, coulombic
interactions. Because the eﬃciency of FRET is inversely pro-
portional to the sixth power of the distance between the donor
and the acceptor, it proves to be a very sensitive and dynamic
tool for the investigation and characterization of the dynamics
of protein–protein interactions.8,9
Selective fluorescence modulation of the proteins of interest
can be considered one of the major challenges in the FRET
technology. Fused FPs overcome this limitation in terms of
selectivity; however, the comparable size of the fusion tags
often hamper the dynamics of the interaction studied.
Selective fluorescent tagging with small organic reporters can
be achieved by the use of smaller fusion tags (SNAP, CyS4 etc.)
or by encoding fluorescent or bioorthogonalized non-canoni-
cal amino acids.10 While these techniques are powerful they
are often laborious and require special skills and advanced
infrastructure. In certain cases, purely chemical modification
can be eﬀected e.g. with reagents harboring a warhead that
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selectively targets rare functions.11 Among the 20 protein-
building amino acids, cysteine is one of the most suitable
targets for such selective reactions because of the low abun-
dance and good nucleophilicity of the free sulfhydryl group.12
Hence, various methods were developed for cysteine bioconju-
gation,13 such as reactions with electrophiles (α-halo carbonyl
derivatives),14 use of Michael acceptors (maleimide deriva-
tives,15 vinyl sulfone16), thiol–yne or –ene reactions,17 disulfide
exchange,18 nucleophilic aromatic substitution of perfluoro-
benzene derivatives,19 or use of allenamide derivatives.20 The
majority of these approaches suﬀer from some limitations,
such as some of the reagents being able to also modify other
nucleophilic amino acid side chains. In the case of Michael-
acceptors the resulting products are often unstable, due to
retro-Michael reactions or in the case of maleimides due to the
fact that the maleimide linkage is prone to hydrolysis.13
Moreover, the thioether group suﬀers from reversible exchange
reactions with reactive thiols. Disulfide conjugates also tend to
participate in exchange reactions,21 while traditional thiol–ene
reactions require nucleophilic or UV-light activation.22 The
vinyl sulfone derivatives successfully addressed these pro-
blems; however, their reaction kinetics is still too slow for
certain in vivo biological experiments.23 Recently, Toda and co-
workers investigated the Julia–Kocienski-like methylsulfonyl-
functionalized heteroaromatic derivatives and presented a new
thiol-selective reagent, which was stable in biological environ-
ments and oﬀered superior reaction kinetics compared to
other thiol-specific reactions.24
In this study, we aimed at investigating protein–protein
interactions using FRET as an indicator of the communication
of model protein p38α (MAPK14) and its direct substrate MK2
(MAPKAP2). Both proteins are the key components of the
mitogen-activated protein kinase signaling pathway.25 p38α is
the main transponder of the inflammatory response, and MK2
plays an important role in the production of inflammatory
cytokines.2
Based on our previous studies26 with p38 and calculations
of solvent accessible surface areas of the proteins, both of
them contain accessible cysteines on their surface regions.
Along the above considerations we designed a bifunctional
chemical reporter tag carrying a thiol-reactive oxadiazole-
methylsulfone and a bioorthogonally reactive cyclooctyne
motif that creates a platform for fluorescent modification. The
fluorescently labeled protein constructs were then used in the
exploration of protein–protein interactions using FRET.
Results and discussion
Synthetic procedures
First, we wanted to screen for FRET pairs from our azide and
tetrazine derivatized dye-pool.27–30 Since photophysical charac-
teristics may substantially change upon conjugation to pro-
teins, we needed a heterobifunctional tag that would enable
Cys-specific targeting on the one hand and allow sequential
one-pot high yielding modification both with azide- and tetra-
zine-modified fluorescent probes. To this end we designed
cyclooctyne bearing methylsulfonyl-oxadiazole 10 (Scheme 1).
The synthesis started with Boc-protection of aminoethoxy-
ethanol, 1, followed by the activation of the hydroxyl group
with tosyl-chloride to provide 3. The product was reacted with
ethyl-hydroxybenzoate under basic conditions to obtain 4 in
excellent yields. Hydrazide 5 was accessed upon treatment of 4
with hydrazine monohydrate.
Oxadiazole 6 was then formed in good yields by a reaction
of hydrazide 5 with carbon disulfide. Methylation of the sulf-
hydryl moiety was eﬀected by treatment of 6 with methyl
iodide to furnish 7. Oxidation of 7 with m-chloroperoxybenzoic
acid gave 8. Acidic removal of the Boc-protecting group quanti-
tatively aﬀorded amine 9. Compound 9 was functionalized
with commercially available BCN–NHS to result in the Cys-
specific heterobifunctional linker 10.
Protein labeling and FRET pair screening
For protein–protein interactions we chose a mutant variant of
p38α where the cysteine at position 162 was replaced by serine
(p38C162S). This site should remain minimally perturbed, as it
is located near the docking site of the protein. For an interact-
ing partner we selected its downstream substrate, the wild
type MAPKAP2 (MK2). Besides mutant p38C162S and MK2 we
extended our study to a 22 amino acid oligopeptide represent-
ing the docking motif of MK2 (CQIKIKKIEDASNPLLLKRRKK,
pepMK2).25
In order to screen for potential FRET pairs, we aimed at
comparing the excitation and emission spectra of our dyes in
their conjugate forms. To this end, we created a bioorthogon-
ally targetable protein scaﬀold using heterobifunctional tag
10, and p38C162S (Scheme 2).
Scheme 1 Reaction conditions: (a) Boc2O, DCM, 0–25 °C, 14 h, 96%;
(b) TsCl, Et3N, DCM, 25 °C, 14 h, quant.; (c) ethyl 4-hydroxybenzoate,
K2CO3, DMF, 60 °C, 14 h, 99%; (d) N2H4 × H2O, EtOH, Δ, 6 h, 99%; (e)
CS2, KOH, EtOH, 85 °C, 14 h, 87%; (f ) CH3I, Et3N, THF, 25 °C, 2 h, quant.;
(g) mCPBA, DCM, 0–25 °C, 14 h, 84%; (h) TFA, H2O, DCM, 25 °C, 1 h,
99%; and (i) BCN–NHS, EDIPA, DCM, 0–25 °C, 90 min, 25%.
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Before labeling, we confirmed that 10 reacts solely with sulf-
hydryls. To do so we allowed 10 to react with glutathione
(GSH). MS measurements (Fig. S1†) aﬃrmed that only the SH-
group participated in the reaction and no N-terminal modifi-
cation was observed. These results are in agreement with the
conclusions of Toda et al.24
Intact whole protein MS measurements verified that com-
plete conversion of p38C162S could be achieved within
10 minutes by adding 2 equivalents of 10 to the protein, result-
ing in a mono-conjugated form of p38C162S with a negligible
amount of any multiply labeled species (Fig. S2 and 3†).
In order to identify the labeling site, tandem mass-spec-
trometry measurements were performed following trypsin
digestion of p38C162S treated with 9 (Fig. S11†). A comparison
of untreated and derivatized p38C162S samples revealed that
the linker reacted mainly at Cys119, which is in accordance
with our former results on calculated accessible surface area
values (Table S1†).26
Next, we wanted to screen for the most promising FRET
pairs in our bioorthogonal dye-pool. For this, we applied the
bifunctional, cyclooctyne bearing chemical reporter 10 on
mutant p38 in sequential labeling experiments with a series of
azide or tetrazine bearing fluorescent or fluorogenic dyes
(11–15). The labeling reactions were conducted in one-pot with
sequential administration of 10 and the respective dyes to the
solution of p38C162S, without any intermediate purification
steps. Such bioorthogonal conjugation of the dyes was very
eﬃcient and in each case the conversion rates reached ca.
100% within 10 minutes, according to intact protein MS ana-
lyses (Fig. S2–8†). Due to the fluorogenic nature of the dyes, no
non-specific signal was observed even if non-specific adhesion
of the dyes onto the surface of the proteins occurred
(Table S3†). The labeled proteins were separated using
SDS-PAGE and imaged under diﬀerent excitation sources. In
each case the dyes labeled the protein successfully (Fig. 1).
Next, we analyzed the excitation and emission spectra of
the dye–protein conjugates to identify donor–acceptor pairs
with overlapping emission and excitation bands. After evaluat-
ing the spectra, we identified a potential FRET pair of 11–12
(Fig. S13a†).
The eﬃciency and selectivity of the conjugation of 10 to
MK2 were also assessed. In this case, addition of 2 equivalents
of 10 to MK2 resulted in mono- and double-conjugated species
as seen from intact whole protein MS measurements
(Fig. S10†). Comparative MS-analysis of labeled and unlabeled,
trypsin digested MK2 samples revealed that the two most
accessible cysteines i.e., Cys224 and Cys98 were involved
(Table S2†).
FRET measurements
To explore the FRET eﬃciency between 11 (Cy1) and 12 (Cy3),
the interacting partners were modified with the dyes applying
the same sequential scheme using 10 as a heterobifunctional
linker (Scheme 2). This way, mutant p38 was labeled with 11,
while MK2 and pepMK2 were tagged with 12 (Fig. S12†).
Following the purification of the fluorescently labeled pro-
teins and peptide, we studied the interaction between Cy1-
conjugated p38C162S and Cy3-conjugated pepMK2 or MK2. The
FRET interaction between labeled p38C162S (0.5 µM) and
increasing amounts of pepMK2 (0 to 8 µM) was monitored
upon excitation of the donor fluorophore (λexc = 420 nm). The
evolution of the FRET signal resulted in a gradual decrease of
the donor fluorescence with a simultaneous increase of the
acceptor’s fluorescence (Fig. 2). FRET eﬃciency was calculated
using the below equation:
EFRET ¼ 100ð1 D=D0Þ;
Scheme 2 Sequential chemical labeling strategy using the heterobi-
functional linker and the bioorthogonalized ﬂuorescent dyes.
Fig. 1 (a) Fluorescent labeling of linker (10) tagged p38C162S with
bioorthogonalized dyes (11–15) monitored by SDS-PAGE. The upper gel
refers to the ﬂuorescence emission at diﬀerent wavelengths (11: 488/
520; 12: 532/580; 13–14: 488/610; and 15: 633/670). The lower gel
shows the result of the Coomassie staining. (b) Excitation and emission
spectra of the listed dyes conjugated to p38C162S.
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where D is the fluorescence intensity of the donor in the pres-
ence of the acceptor at 482 nm at diﬀerent concentrations and
D0 is the fluorescence intensity of the donor, in the absence of
the acceptor. As seen in the inset of Fig. 2b the curve reached
the saturation value at a remarkably high, 87% FRET-
eﬃciency. This high FRET signal is in good accordance with
the estimated short distance (10.6 Å) of the pepMK2 cysteine
and the labeled Cys119 in p38 (according to the structure of
the protein PDB code 2OZA).31 The dissociation constant (Kd =
240 nM; see the ESI†) for pepMK2 was calculated to be slightly
higher than the literature data (i.e. 50 nM) obtained for wild
type p38α.25 The diﬀerence can be attributed to the altered
interactions caused by mutation at position 162 of p38 as well
as the presence of the additional Cys residue at the N-terminal
of the peptide. Diﬀerences in the measurement methods can
also be the reason e.g., fluorescence vs. polarization.
Systematic comparative measurements supported this hypoth-
esis (for more details cf. ESI part S7†).
In the case of the protein–protein interactions similar con-
ditions were applied (Fig. 3). Signal changes were monitored at
the same wavelengths upon interaction of fluorescently labeled
Cy1-p38C162S with increasing amounts of Cy3-labeled MK2
(0 to 4 µM). For the calculation of the FRET eﬃciency the same
equation was used; however, eﬀects of protein interaction on
donor fluorescence were taken into account as the presence of
MK2 creates a less-polar environment for the donor resulting
in an increase of the fluorescence intensity. Thus, the fluo-
rescence intensity of the donor fluorophore in the presence of
acceptor labeled MK2 was always normalized with the fluo-
rescence intensity of the donor, in the presence of unlabeled
MK2 at the respective concentrations (Fig. S15†). The FRET
eﬃciency went to saturation at 74% (Fig. 3b). Both cysteines
were located within the critical distance i.e., 100 Å necessary
for eﬃcient FRET (dCys224 = 29.8 Å and dCys98 = 23.7 Å accord-
ing to the structure of the protein complex PDB code 2OZA).31
The decreased FRET eﬃciency compared to the p38C162S–
pepMK2 interaction could be explained by the longer distance
between the labeling sites. The binding aﬃnity between p38
and MK2 protein was found to be Kd = 145 nM (see the ESI†).
Estimated Kd values in the literature vary between 1 and 100
nM depending on the amino acid sequence, the size of the
given fragment, the activity (phosphorylation) state of the
interacting molecules and the ionic strength of the media.32
The high salt concentration – applied in order to prevent
the aggregation of MK2 – was concomitant of lower aﬃnity in
our setup.
Conclusions
In conclusion, we demonstrated the synthesis and use of a
heterobifunctional linker that enables highly specific and
eﬃcient modification of proteins via free-sulfhydryl functional-
ities of cysteine residues through its methylsulfonyl-oxadiazole
warhead. The cyclooctyne functionalized bifunctional methyl-
Fig. 2 (a) The structure of the complex of protein p38C162S (based on
PDB code 2OZA) and peptide MK2. The accessible cysteines are high-
lighted in yellow. (b) Changes in ﬂuorescence upon interaction between
the Cy1-labeled p38C162S and Cy3-labeled peptide MK2 (inset shows the
calculated FRET-eﬃciency).
Fig. 3 (a) The structure of the complex of protein p38C162S and protein
MK2 (based on PDB code 2OZA). The accessible cysteines are high-
lighted in green. (b) The FRET signal between Cy1-labeled p38C162S and
Cy3-labeled protein MK2 (inset shows the calculated FRET-eﬃciency).
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sulfonyl linker readily creates a bioorthogonal platform that
oﬀers easy and high-yielding modification with azide or tetra-
zine modified fluorescent probes. First, we used this heterobi-
functional linker to screen for possible FRET pairs from our
existing bioorthogonalized fluorescent pool. Following the
identification of a promising FRET pair, we used this Cys-
specific linker to modify p38C162S and its interacting partner
MK2 or its docking motif pepMK2 with a FRET donor and
acceptor, respectively. Tandem-MS measurements verified the
selective and specific labeling of both protein components.
FRET studies involving donor and acceptor labeled p38C162S–
MK2 or p38C162S–pepMK2 partners confirmed the specific
interactions of the proteins. Such heterobifunctional linkers
are suitable for the selective modification of proteins posses-
sing accessible free sulfhydryl functionalities. On the other
hand, the high FRET eﬃciency between the identified dye
pairs (ca. 80%) is suitable for the detection of protein–protein
interactions and estimation of the strength of aﬃnity.
Experimental
Organic syntheses
General methods. Unless otherwise indicated, all starting
materials were obtained from commercial suppliers (Sigma-
Aldrich, Fluka, Merck, Alfa Aesar, Reanal, Molar Chemicals,
Fluorochem) and used without further purification. The
fluorogenic dyes (11–15) were prepared as described pre-
viously. Analytical thin-layer chromatography (TLC) was per-
formed on silica gel 60 F254 precoated aluminium TLC plates
from Merck. Visualization of TLC samples was performed
using a 254/365 nm UV lamp and/or KMnO4 stain. Column
chromatography was carried out with silica gel (0.06–0.2 mm)
purchased from Zeochem. Ratios of the solvents for the
eluents are given in volumes (mL/mL). Flash column chrom-
atography was performed on a CombiFlash Rf+System
(Teledyne ISCO, Lincoln, NE, USA). NMR spectra were recorded
on Varian Inova 500 MHz and Varian 600 MHz NMR spec-
trometers. Chemical shifts (δ) are given in parts per million
(ppm) using solvent signals as the reference. Coupling con-
stants (J) are reported in hertz (Hz). Splitting patterns are
designated as s (singlet), d (doublet), t (triplet), qr (quadru-
plet), qv (quintuplet), m (multiplet), dd (doublet of a doublet),
td (triplet doublet), dt (doublet triplet), and brs (broad
singlet). The exact masses were determined using an Agilent
6230 time-of-flight mass spectrometer. All melting points were
measured on an OptiMelt Automated Melting Point System
and are uncorrected.
Synthesis of tert-butyl (2-(2-hydroxyethoxy)ethyl)carbamate
(2). To a solution of 2-(2-aminoethoxy-ethan-1-ol) (1.04 mL;
10.37 mmol) in CH2Cl2 (60 mL) di-tert-butyl-dicarbonate
(2.26 g; 10.37 mmol) was added, and the reaction mixture was
stirred at room temperature for 18 h. After the evaporation of
the solvent the crude product was purified by silica gel column
chromatography (hexane/ethyl acetate = 1/3) to yield 2.05 g
product as a colorless oil (96%). Rf = 0.29 (hexane/ethyl acetate
= 1/1). 1H NMR (500 MHz, CDCl3) δ 3.71–3.68 (m, 2H),
3.55–3.50 (m, 4H), 3.29 (t, J = 5.1 Hz, 2H), 1.41 (s, 9H). 13C
NMR (126 MHz, CDCl3) δ 156.3, 79.5, 72.4, 70.4, 61.8, 40.6,
28.5 (Fig. S16†). HRMS: [M + Na]+ calcd for [C9H19NO4Na
+] m/z
228.1212, found m/z 228.1211.
2-(2-((tert-Butoxycarbonyl)amino)ethoxy)ethyl 4-methyl-
benzenesulfonate (3). A solution of 2 (2.05 g; 10 mmol) and tri-
ethylamine (4.9 mL; 35 mmol) in CH2Cl2 (25 mL) was cooled
to 0 °C. p-Toluenesulfonyl chloride (5.72 g; 30 mmol) dissolved
in CH2Cl2 (10 mL) was added and the reaction mixture was
allowed to warm to room temperature and stirred for 18 hours.
Solids were filtered out and the filtrate was washed with 10%
citric acid (3 × 100 mL) and brine (1 × 100 mL) and dried over
MgSO4. After filtration the solvent was removed in vacuo and
the crude product was purified by silica gel column chromato-
graphy (hexane/ethyl acetate = 3/1) to yield 6.13 g (68%) of a
colorless oil. Rf = 0.54 (hexane/ethyl acetate = 1/1).
1H NMR
(500 MHz, CDCl3) δ 7.79 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.0 Hz,
2H), 4.78 (s, 1H), 4.16–4.13 (m, 2H), 3.63–3.60 (m, 2H), 3.43 (t,
J = 5.1 Hz, 2H), 3.22 (t, J = 4.8 Hz, 2H), 2.43 (s, 3H), 1.43 (s,
9H). 13C NMR (126 MHz, CDCl3) δ 156.0, 145.0, 133.2, 129.9,
128.1, 79.5, 70.5, 69.2, 68.5, 40.4, 28.5, 21.7 (Fig. S17†). HRMS:
[M + Na]+ calcd for [C16H25NO6SNa]
+ m/z 382.1300, found m/z
382.1296.
Synthesis of ethyl 4-(2-(2-((tert-butoxycarbonyl)-amino)
ethoxy)ethoxy)benzoate (4). Ethyl 4-hydroxybenzoate (0.92 g,
5.54 mmol), compound 3 (2.00 g, 5.54 mmol) and dry K2CO3
(2.30 g, 16.62 mmol) were dissolved in anhydrous DMF
(20 mL) under a N2 atmosphere and stirred overnight at 60 °C.
After cooling down the reaction mixture was diluted with
80 mL CH2Cl2 and washed with 3 × 80 mL water, 80 mL brine
and dried over MgSO4. After evaporation of the solvent the
crude product was purified by silica gel column chromato-
graphy with hexane/ethyl acetate = 10/1–1/1 to yield 1.94 g
(99%) product as white crystals. Rf = 0.67 (hexane/ethyl acetate
= 1/1). Mp = 48–52 °C. 1H NMR (500 MHz, CD3OD): δ 8.03 (d,
J = 8.9 Hz, 2H), 7.09 (d, J = 8.9 Hz, 2H), 4.40 (q, J = 7.1 Hz, 2H),
4.29–4.26 (m, 2H), 3.92–3.89 (m, 2H), 3.65 (t, J = 5.7 Hz, 2H),
3.32 (t, J = 5.6 Hz, 2H), 1.50 (s, 9H), 1.44 (t, J = 7.1 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 166.5, 162.5, 133.0, 131.7, 123.4,
114.3, 110.2, 70.7, 69.4, 67.6, 60.8, 57.8, 28.6, 14.5 (Fig. S18†).
HRMS: [M + Na]+ calcd for [C18H27NO6Na]
+ m/z 376.1736,
found m/z 376.1735.
Synthesis of tert-butyl (2-(2-(4-(hydrazinecarbonyl)phenoxy)-
ethoxy)ethyl)carbamate (5). In a round-bottomed flask 4
(1.92 g; 5.44 mmol) and hydrazine monohydrate (792 µL;
16.32 mmol) were heated under reflux for 30 min. Then
ethanol was added (1.3 mL) and the mixture was stirred at the
reflux temperature for 6 hours. After evaporation of the solvent
the residue was purified by silica gel column chromatography
(ethyl acetate/MeOH = 20/1) to give 5 as a colorless oil (1.83 g,
99%). Rf = 0.31 (ethyl acetate/MeOH = 20/1).
1H NMR
(500 MHz, DMSO-d6): δ 7.82 (d, J = 8.6 Hz, 2H), 7.14 (d, J = 8.8
Hz, 2H), 6.75 (t, J = 5.3 Hz, 1H), 4.21–4.17 (m, 2H), 3.77–3.73
(m, 2H), 3.46 (t, J = 6.0 Hz, 2H), 3.09 (q, J = 6.0 Hz, 2H), 1.37 (s,
9H). 13C NMR (126 MHz, CDCl3) δ 168.2, 161.7, 156.1, 128.9,
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125.2, 114.6, 70.6, 69.3, 67.6, 50.7, 40.4, 28.5 (Fig. S19†).
HRMS: [M + H]+ calcd for [C16H26N3O5]
+ m/z 340.1872, found
m/z 340.1863.
Synthesis of tert-butyl (2-(2-(4-(5-mercapto-1,3,4-oxadiazol-2-
yl)phenoxy)ethoxy)ethyl)carbamate (6). To a solution of 5
(2.00 g, 5.88 mmol) in ethanol (14 mL) carbon disulfide
(2.34 mL, 38.81 mmol) and KOH (330 mg, 5.88 mmol) were
added and the solution was stirred at 85 °C overnight. After
cooling to room temperature, the mixture was diluted with
ethyl acetate (100 mL) and washed with 1 M HCl (2 × 80 mL)
and brine (100 mL) and dried over MgSO4. The crude product
was purified by silica gel column chromatography (hexane/
ethyl acetate = 2/1–1/9) to yield 1.95 g (87%) of a white solid.
Rf = 0.57 (hexane/ethyl acetate = 1/9). Mp = 76–82 °C.
1H NMR
(500 MHz, CDCl3): δ 12.51 (s, 1H), 7.75 (d, J = 8.1 Hz, 2H), 6.95
(d, J = 8.6 Hz, 2H), 5.21 (s, 1H), 4.23–4.14 (m, 2H), 3.87 (d, J =
4.0 Hz, 2H), 3.66 (t, J = 5.0 Hz, 2H), 3.39 (s, 2H), 1.45 (s, 9H).
13C NMR (126 MHz, CDCl3) δ 177.8, 161.8, 156.5, 128.9, 128.2,
116.3, 115.1, 70.4, 69.2, 67.5, 40.3, 28.4, 11.4 (Fig. S20†).
HRMS: [M + Na]+ calcd for [C17H23N3O5SNa]
+ m/z 404.1256,
found m/z 404.1263.
Synthesis of tert-butyl (2-(2-(4-(5-(methylthio)-1,3,4-oxadi-
azol-2-yl)phenoxy)ethoxy)ethyl)carbamate (7). Compound 6
(3.03 g, 7.93 mmol) was dissolved in THF (50 mL) and cooled
to 0 °C. Then CH3I (592 µL, 9.52 mmol) and Et3N (1.33 mL,
9.52 mmol) were added and the mixture was stirred for 2 h at
room temperature. After evaporation of the solvent ethyl
acetate was added (200 mL) and the mixture was extracted with
water (3 × 100 mL). The water phase was washed with ethyl
acetate (2 × 100 mL). The combined organic phase was washed
with brine (200 mL) and dried over MgSO4. The crude product
was dissolved in Et2O (10 mL), and hexane was added drop-
wise. The solvents were removed using a pipette from the pale
yellow oil formed and it was washed again. After evaporation
to dryness the product appeared as a white solid (3.14 g; 90%).
Rf = 0.76 (ethyl acetate/methanol = 9/1); 0.25 (hexane/ethyl
acetate = 1/1). Mp = 42–44 °C. 1H NMR (500 MHz, CDCl3): δ
7.91 (d, J = 8.9 Hz, 2H), 7.00 (d, J = 8.9 Hz, 2H), 4.96 (s, 1H),
4.18–4.14 (m, 2H), 3.85–3.81 (m, 2H), 3.60 (t, J = 5.1 Hz, 2H),
3.33 (d, J = 4.8 Hz, 2H), 2.74 (s, 3H), 1.42 (s, 9H). 13C NMR
(126 MHz, CDCl3): δ 165.8, 164.4, 161.5, 156.1, 128.5, 116.6,
115.2, 79.4, 70.6, 69.4, 67.7, 40.4, 28.5, 14.8 (Fig. S21†). HRMS:
[M + H]+ calcd for [C18H26N3O5S
+] m/z 396.1583, found m/z
396.1593.
Synthesis of tert-butyl (2-(2-(4-(5-(methylsulfonyl)-1,3,4-oxa-
diazol-2-yl)phenoxy)ethoxy)ethyl)carbamate (8). Compound 7
(1.98 mg, 5.0 mmol) was dissolved in CH2Cl2 (40 mL), and
cooled to 0 °C. mCPBA (70 wt%; 3.19 g; 18.5 mmol) was added
and the mixture was stirred at room temperature overnight.
After filtration of the insoluble material the solvent was evap-
orated, and the residue was purified by silica gel column
chromatography (hexane/ethyl acetate = 2/1–ethyl acetate/
MeOH = 9/1) which gave the title compound 8 (1.77 g, 84%) as
a white solid. Rf = 0.25 (hexane/ethyl acetate = 1/1). Mp =
118–120 °C. 1H NMR (500 MHz, DMSO-d6): δ 8.03 (d, J = 8.8
Hz, 2H), 7.21 (d, J = 8.8 Hz, 2H), 6.76 (s, 1H), 4.26–4.19 (m,
2H), 3.79–3.74 (m, 2H), 3.69 (s, 3H), 3.47 (t, J = 6.0 Hz, 2H),
3.10 (q, J = 5.8 Hz, 2H), 1.37 (s, 9H). 13C NMR (126 MHz,
DMSO-d6): δ 165.7, 162.2, 161.6, 155.6, 142.0, 129.4, 115.5,
114.2, 77.5, 69.3, 68.4, 67.6, 42.9, 28.2 (Fig. S22†). HRMS:
[M + Na]+ calcd for [C18H25N3O7SNa]
+ m/z 450.1311, found m/z
450.1315.
Synthesis of 2-(2-(4-(5-(methylsulfonyl)-1,3,4-oxadiazol-2-yl)
phenoxy)ethoxy)ethan-1-aminium 2,2,2-trifluoroacetate (9). To
a solution of compound 8 (269 mg, 0.63 mmol) in CH2Cl2
(5 mL), H2O (20 µL) and TFA (1 mL) were added and the
mixture was stirred for 1 h at room temperature. After com-
pletion of the reaction (checked by TLC) the solvents were
evaporated using N2 and the crude product was washed with
Et2O (3 × 3 mL). The product precipitates as oﬀ-white crystals
(240 mg, 80%). Mp = 146–148 °C. 1H NMR (500 MHz, CD3OD):
δ 8.09 (d, J = 8.8 Hz, 2H), 7.19 (d, J = 8.8 Hz, 2H), 4.35–4.29 (m,
2H), 3.99–3.96 (m, 2H), 3.86–3.83 (m, 2H), 3.59 (s, 3H), 3.35 (s,
1H), 3.21 (t, J = 4.8 Hz, 2H). 13C NMR (126 MHz, CD3OD) δ
168.0, 164.2, 163.5, 130.7, 116.5, 116.0, 70.6, 69.0, 68.1, 43.3,
40.7 (Fig. S23†). HRMS: [M]+ calcd for [C13H18N3O5S]
+ m/z
328.0967, found m/z 328.0962.
Synthesis of bicyclo[6.1.0]non-4-yn-9-ylmethyl (2-(2-(4-(5-
(methylsulfonyl)-1,3,4-oxadiazol-2-yl)phenoxy)ethoxy)ethyl)-
carbamate (10). Compound 9 (30 mg; 0.07 mmol) and EDIPA
(35 μL; 0.20 mmol) were dissolved in CH2Cl2 (4 mL) and
cooled to 0 °C. BCN–succinimidyl carbonate (24 mg;
0.08 mmol) was added and stirred for 3 h at room tempera-
ture. After evaporation of the solvent the residue was purified
by flash chromatography using CH2Cl2/MeOH = 100/1–30/1 to
yield the product (13 mg; 37%) as a colorless oil. Rf = 0.35
(CH2Cl2/MeOH = 30/1).
1H NMR (500 MHz, CDCl3) δ 8.06 (d,
J = 8.9 Hz, 2H), 7.06 (d, J = 8.9 Hz, 2H), 5.06 (s, 1H), 4.22–4.19
(m, 2H), 4.14 (d, J = 8.0 Hz, 2H), 3.87–3.83 (m, 2H), 3.64 (t, J =
5.1 Hz, 2H), 3.50 (s, 3H), 3.40 (dd, J = 10.5, 5.2 Hz, 2H),
2.34–2.12 (m, 6H), 1.59–1.51 (m, 2H), 1.40–1.30 (m, 1H), 0.93
(t, J = 9.7 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 162.9, 161.8,
156.9, 129.8, 128.9, 115.6, 114.8, 98.9, 70.6, 69.4, 67.9, 63.0,
53.9, 43.1, 29.2, 21.6, 20.3, 17.9 (Fig. S24†). HRMS: [M + H]+
calcd for [C24H30N3O7S]
+ m/z 504.1804, found m/z 504.1797.
Peptide synthesis and protein expression and purification
PepMK2. The peptide was synthesized using a standard
Fmoc-SPPS protocol. It was synthesized on Rink Amid MBHA
resin (Protein Technologies, Inc.) using a peptide synthesizer
(PS3, Protein Technologies, Inc.). Coupling reactions used
Fmoc-L-amino acid/HBTU/NMM (5/4/10 eq.) in DMF (peptide
synthesis grade). A cleaving solution of 5 mL of TFA/H2O/TIS
(95/2.5/2.5% v/v) was added to the resin, and mixed for 2 h.
The crude peptide was purified using semi-preparative HPLC
(Jupiter 10 µm C18 300 Å, LC Column 250 × 10 mm;
Phenomenex, Torrance, CA, USA).
MK2 protein. The cDNA of the MK2 human protein DNA
construct containing residues between 41 and 400 was cloned
into a modified pET expression vector. cDNA encoding the
MK2 construct was produced from HEK293 derived mRNA.
The MK2 construct was expressed in Escherichia coli Rosetta
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(DE3) pLysS (Novagen) cells. The expressed MK2 construct con-
tained an N-terminal cleavable GST-tag and a C-terminal
uncleavable hexahistidine-tag. Protein purification involved
two steps: Ni- and then GST-aﬃnity chromatography. The GST
tag was removed by tobacco etch virus protease. Finally, the
MK2 protein was purified again by Ni-aﬃnity chromatography
to remove the cleaved GST.
p38C162S protein. The protein expression was carried out
according to our previously reported procedure.23
Conjugation processes
Conjugation of model proteins and fluorescent linkers. In
the case of p38C162S, 60 µM protein and 120 µM linker 10 were
mixed and incubated for 10 minutes at room temperature in
the dark in PBS buﬀer (pH 7.4). In the second step, an appro-
priate dye (11–15) was added in 240 µM concentration for
10 min, too. The excess reagents were removed by using a
SpinPrep column (Sigma, St Louis, MO, USA) filled with
Sephadex G-25 “Fine” desalting gel (Pharmacia Fine
Chemicals, Sweden). In the case of MK2, 60 µM protein and
120 µM linker 10 were mixed and incubated for 10 minutes at
room temperature in the dark in PBS buﬀer (pH 7.4) com-
pleted with additional 160 mM NaCl, 0.1% IGEPAL and
400 µM TCEP. In the second step dye 12 was added. The excess
reagents were removed by using a SpinPrep column filled with
Sephadex G-25 “Fine” desalting gel.
Fluorescent conjugation of pepMK2. 500 µM peptide, 1 mM
TCEP and 3 mM of compound [10 + 12] were mixed and incu-
bated for 1 hour at room temperature in the dark in 50 mM
HEPES buﬀer (pH 8.0). It was purified by HPLC (Phenomenex
Jupiter 10 µm Proteo C18 90 Å, LC Column 250 × 10 mm)
using H2O + 0.1% TFA as eluent A and CH3CN + 0.1% TFA as
eluent B and the product was lyophilized.
SDS polyacrylamide gel electrophoresis. The samples were
diluted with a sample buﬀer (250 mM Tris-HCl (pH 6.8) + 10%
SDS + 40% glycerol + 0.02% bromophenol blue + 400 mM
DTT) in a 3 : 1 ratio. The size of the polyacrylamide gels was
8.5 cm × 7.5 cm × 0.1 cm. They were the combination of 4%
concentration and 10% separation PAGE gels (acrylamide/
bisacrylamide ratio was 29/1; and concentration gel buﬀer was
125 mM Tris-HCl + 0.1% SDS (pH 6.8) and the separation gel
buﬀer was 375 mM Tris-HCl + 0.1% SDS (pH 8.8)). 7.5 µg of
protein was loaded per lane. A Prestained PAGERuler Plus
(Thermo Fisher Scientific) was applied as the molecular weight
standard. Separations were carried out in a Mini-Protean Tetra
Cell (Bio-Rad, Hercules, CA, USA) using 25 mM Tris/192 mM
glycine + 0.1% SDS (pH 8.3) as the running buﬀer and 180 V
voltage for 40 min at 25 °C. The gels were documented by
using a Typhoon Trio Imaging System (GE Healthcare,
Uppsala, Sweden). Furthermore, the gels were stained for pro-
teins with Coomassie Brilliant-Blue.
FRET measurements
The labeled p38C162S samples were prepared in 1.0 µM concen-
tration in PBS (pH 7.4) buﬀer. The labeled MK2 peptide and
protein samples were prepared in 16, 8, 4, 2, 1, 0.5, 0.25, 0.125,
0.0625, and 0.03125 µM concentrations for the titration. From
the appropriate solutions 10 + 10 µL were transferred into the
wells. The FRET interactions between the two labeled partners
were monitored based on the generation of the fluorescence
signal (λex: 420 nm; λem: 450–700 nm) by using a PerkinElmer
Enspire Multimode Reader (PerkinElmer Inc.; Waltham, MA,
USA) in a 384-well round bottom black plate (Corning,
Corning, NY, USA) at room temperature with 100 flashes per
point. Data were acquired and handled by Corning Enspire
Manager 4.10 software.
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